Fang M, Ye L, Zhu Y, Huang L, Xu S
Biomolecules. 2025; 15(2).
PMID: 40001461
PMC: 11853652.
DOI: 10.3390/biom15020157.
Yang P, Wang H, Meng L, Kou Y, Bu J, Li M
J Mol Histol. 2025; 56(2):86.
PMID: 39928245
DOI: 10.1007/s10735-025-10358-x.
Wang Y, Li X, Liu C, Zhou L, Shi L, Zhang Z
Life Metab. 2025; 1(3):270-284.
PMID: 39872074
PMC: 11749075.
DOI: 10.1093/lifemeta/loac028.
Li N, Wei X, Dai J, Yang J, Xiong S
Mol Cell Biochem. 2025; .
PMID: 39853661
DOI: 10.1007/s11010-025-05208-z.
Wang Y, Zou J, Zhou H
Front Endocrinol (Lausanne). 2024; 15:1462146.
PMID: 39296713
PMC: 11408340.
DOI: 10.3389/fendo.2024.1462146.
The Roles of RNA N6-methyladenosine Modifications in Systemic Lupus Erythematosus.
Xia X, Qu R
Cell Biochem Biophys. 2024; 82(4):3223-3234.
PMID: 39095568
DOI: 10.1007/s12013-024-01464-w.
Changes of RNA mA/mC Modification Regulatory Molecules in Ferroptosis of T2DM Rat Pancreas.
Liu X, Wang N, Gu S, He Z
Cell Biochem Biophys. 2024; 82(2):1279-1289.
PMID: 38709441
DOI: 10.1007/s12013-024-01282-0.
The regulatory role of mA methylation modification in metabolic syndrome pathogenesis and progression.
Ye D, Zhang Y, Zhang B, Liu J, Wei T, Lu S
Front Physiol. 2024; 15:1271874.
PMID: 38562618
PMC: 10984216.
DOI: 10.3389/fphys.2024.1271874.
-methyladenosine modification in ischemic stroke: Functions, regulation, and therapeutic potential.
Han F
Heliyon. 2024; 10(3):e25192.
PMID: 38317953
PMC: 10840115.
DOI: 10.1016/j.heliyon.2024.e25192.
The role of N-methyladenosine modification in acute and chronic kidney diseases.
Qi S, Song J, Chen L, Weng H
Mol Med. 2023; 29(1):166.
PMID: 38066436
PMC: 10709953.
DOI: 10.1186/s10020-023-00764-w.
Hepatocyte-specific deletion of promotes hepatocellular carcinoma in mice.
Liu C, Li X, Yao Z, Li X, Chen Z
Genes Dis. 2023; 11(1):57-59.
PMID: 37671390
PMC: 10475669.
DOI: 10.1016/j.gendis.2023.02.048.
N-adenosine methylation controls the translation of insulin mRNA.
Wilinski D, Dus M
Nat Struct Mol Biol. 2023; 30(9):1260-1264.
PMID: 37488356
PMC: 11756593.
DOI: 10.1038/s41594-023-01048-x.
N6-methyladenosine RNA modification: an emerging molecule in type 2 diabetes metabolism.
Zhang H, Gu Y, Gang Q, Huang J, Xiao Q, Ha X
Front Endocrinol (Lausanne). 2023; 14:1166756.
PMID: 37484964
PMC: 10360191.
DOI: 10.3389/fendo.2023.1166756.
The role of mA and mAm RNA modifications in the pathogenesis of diabetes mellitus.
Benak D, Benakova S, Plecita-Hlavata L, Hlavackova M
Front Endocrinol (Lausanne). 2023; 14:1223583.
PMID: 37484960
PMC: 10360938.
DOI: 10.3389/fendo.2023.1223583.
Downregulation of hepatic METTL3 contributes to APAP-induced liver injury in mice.
Liu C, Li X, Gao M, Dong Y, Chen Z
JHEP Rep. 2023; 5(8):100766.
PMID: 37456679
PMC: 10338307.
DOI: 10.1016/j.jhepr.2023.100766.
Epitranscriptomics in metabolic disease.
Matsumura Y, Wei F, Sakai J
Nat Metab. 2023; 5(3):370-384.
PMID: 36959512
DOI: 10.1038/s42255-023-00764-4.
Deficiency of WTAP in islet beta cells results in beta cell failure and diabetes in mice.
Li X, Yang Y, Li Z, Wang Y, Qiao J, Chen Z
Diabetologia. 2023; 66(6):1084-1096.
PMID: 36920524
DOI: 10.1007/s00125-023-05900-z.
The Epigenetic Regulation of RNA N6-Methyladenosine Methylation in Glycolipid Metabolism.
Yang H, Li Y, Huang L, Fang M, Xu S
Biomolecules. 2023; 13(2).
PMID: 36830642
PMC: 9953413.
DOI: 10.3390/biom13020273.
The Effect of N6-Methyladenosine Regulators and m6A Reader YTHDC1-Mediated N6-Methyladenosine Modification Is Involved in Oxidative Stress in Human Aortic Dissection.
Yin F, Liu K, Peng W, Jiang D, Zhang H, Guo P
Oxid Med Cell Longev. 2023; 2023:3918393.
PMID: 36819785
PMC: 9935809.
DOI: 10.1155/2023/3918393.
N6-Methyladenosine Methyltransferase METTL3 Alleviates Diabetes-Induced Testicular Damage through Modulating TUG1/Clusterin Axis.
Tian Y, Xiao Y, Sun C, Liu B, Sun F
Diabetes Metab J. 2023; 47(2):287-300.
PMID: 36653890
PMC: 10040629.
DOI: 10.4093/dmj.2021.0306.